-
1.发明授权NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES 有权含氮二环杂用于疾病治疗由RAF蛋白激酶介导BE
公开(公告)号：EP1976836B1
公开(公告)日：2012-08-22
申请号：EP06848110.0
申请日：2006-12-22
申请人： Amgen Inc.
发明人： DE MORIN, Frenel, F. , CHEN, Jian J. , DOHERTY, Elizabeth M. , HITCHCOCK, Stephen , HUANG, Qi , KIM, Joseph, L. , LIU, Gang , NIXEY, Thomas , PARAS, Nick, A. , PETKUS, Jeffrey , RETZ, Daniel, M. , SMITH, Adrian, L. , TASKER, Andrew , ZHU, Jiawang
IPC分类号： C07D239/84 , C07D239/95 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/435 , A61K31/495 , A61K31/55 , C07D471/04 , C07D487/04 , C07D495/04 , C07D413/04
CPC分类号： C07D401/14 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
-
2.发明授权NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES 有权含氮二环杂用于疾病治疗由RAF蛋白激酶介导BE
公开(公告)号：EP1976836B9
公开(公告)日：2013-02-06
申请号：EP06848110.0
申请日：2006-12-22
申请人： Amgen Inc.
发明人： DE MORIN, Frenel, F. , CHEN, Jian J. , DOHERTY, Elizabeth M. , HITCHCOCK, Stephen , HUANG, Qi , KIM, Joseph, L. , LIU, Gang , NIXEY, Thomas , PARAS, Nick, A. , PETKUS, Jeffrey , RETZ, Daniel, M. , SMITH, Adrian, L. , TASKER, Andrew , ZHU, Jiawang
IPC分类号： C07D239/84 , C07D239/95 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/435 , A61K31/495 , A61K31/55 , C07D471/04 , C07D487/04 , C07D495/04 , C07D413/04
CPC分类号： C07D401/14 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04
-
3.发明公开NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES 有权含氮二环杂用于疾病治疗由RAF蛋白激酶介导BE
公开(公告)号：EP1976836A2
公开(公告)日：2008-10-08
申请号：EP06848110.0
申请日：2006-12-22
申请人： Amgen Inc.
发明人： DE MORIN, Frenel, F. , CHEN, Jian J. , DOHERTY, Elizabeth M. , HITCHCOCK, Stephen , HUANG, Qi , KIM, Joseph, L. , LIU, Gang , NIXEY, Thomas , PARAS, Nick, A. , PETKUS, Jeffrey , RETZ, Daniel, M. , SMITH, Adrian, L. , TASKER, Andrew , ZHU, Jiawang
IPC分类号： C07D239/84 , C07D239/95 , C07D401/04 , C07D401/14
CPC分类号： C07D401/14 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04
摘要： The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have Formula (I) wherein R1 is Formula (II), (III) or (IV) and A1, A2, A3, A4, X, Z, Z', R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
-
-
搜索结果
3 条记录 (耗时 0.013 秒)
